TRT & Hair Loss: Understanding DHT, Genetics, and Prevention

Last Updated: OCTOBER 2023

Men with total testosterone below 300 ng/dL have a 2.4 times higher cardiovascular mortality risk compared to those with levels above 600 ng/dL, as reported in the Journal of Clinical Endocrinology & Metabolism (JCEM, 2018). Optimizing testosterone levels is a critical component of men’s health, yet concerns about potential side effects like androgenic alopecia (AGA), or male pattern baldness, frequently arise. Understanding the interplay between testosterone replacement therapy (TRT), dihydrotestosterone (DHT), and genetic predisposition is crucial for men who want to optimize their hormones while preserving their hairline. TRT is not a treatment for scalp hair loss; rather, in genetically predisposed individuals, it can paradoxically accelerate thinning.

The Androgen-Hair Follicle Connection

Androgenic alopecia is primarily a genetic condition. It is not “caused” by high testosterone but rather by the sensitivity of hair follicles to androgens, specifically dihydrotestosterone (DHT). Testosterone circulates in the body, and a portion of it is converted into DHT by the enzyme 5-alpha reductase (5AR). DHT is significantly more potent than testosterone in stimulating androgen receptors. In genetically susceptible individuals, these receptors in scalp hair follicles, particularly at the temples and crown, are hypersensitive to DHT. This leads to a process called miniaturization, where hair follicles shrink over time, producing progressively finer, shorter, and less pigmented hairs until they eventually cease production entirely.

When you start TRT, protocols typically involve injections of testosterone cypionate or enanthate, often dosed at 100–200mg per week, administered intramuscularly or subcutaneously. This raises systemic testosterone levels into an optimal range, typically aiming for total testosterone between 700–1000 ng/dL and free testosterone between 15–25 pg/mL. With more circulating testosterone, there is a greater substrate for the 5AR enzyme to convert into DHT. For those genetically predisposed, this increased DHT exposure can accelerate the rate of hair miniaturization and loss. It’s important to understand that TRT doesn’t initiate hair loss in those without the genetic predisposition; it merely amplifies an existing genetic tendency. The notion that a “low” testosterone level, perhaps below the archaic 264 ng/dL threshold (calibrated from a 1970s population including sick, elderly men), is protective against hair loss is misleading if a man is still genetically predisposed. Even at lower baseline T levels, if 5AR activity is high and follicles are sensitive, hair loss can occur.

The Role of DHT in Hair Follicle Miniaturization

DHT is the primary androgen responsible for androgenic alopecia. While testosterone is essential for many bodily functions, including muscle growth, libido, and bone density, DHT’s potent effect on susceptible hair follicles is its double-edged sword for men seeking hormone optimization. The concentration of DHT in hair follicles can increase by around 27–53% with oral finasteride administration, even at low doses, indicating the significant local conversion. This local concentration is key; systemic DHT levels do not always perfectly reflect follicular levels.

Strategies for Managing Hair Loss on TRT

Managing androgenic alopecia while on TRT involves a multi-pronged approach, focusing on reducing DHT’s impact on hair follicles while maintaining optimal testosterone levels. The goal is to minimize follicular exposure to DHT without compromising the benefits of TRT.

1. 5-Alpha Reductase Inhibitors (5ARIs)

These medications work by blocking the enzyme 5-alpha reductase, thereby preventing the conversion of testosterone to DHT.

• Finasteride: This medication specifically inhibits Type II 5-alpha reductase.
  • Mechanism: Reduces scalp and serum DHT levels by approximately 70%.
  • Dosage: An oral dosage of finasteride of only 0.2 mg/day has been found to achieve near-maximal suppression of DHT levels (68.6% for 0.2 mg/day relative to 72.2% for 5 mg/day), as detailed on Finasteride - Wikipedia. Common dosages for hair loss are often 1mg daily.
  • Efficacy: Highly effective at preventing further hair loss and promoting regrowth, particularly in the crown and mid-scalp regions. It is generally superior for the frontal hairline specifically, as it directly blocks DHT at the follicle.
  • Considerations: While generally well-tolerated, a small percentage of men report side effects like decreased libido, erectile dysfunction, or gynecomastia. These side effects are often dose-dependent and reversible upon cessation. Monitoring estradiol (E2) levels, aiming for 20–40 pg/mL on TRT, is crucial to differentiate finasteride-induced gynecomastia from high E2-induced issues, as finasteride does not impact E2 directly.
• Dutasteride: Inhibits both Type I and Type II 5-alpha reductase, leading to an even greater reduction in DHT levels (approximately 90%).
  • Mechanism: Broader inhibition of 5AR types.
  • Dosage: Typically 0.5 mg daily.
  • Efficacy: Often considered more potent than finasteride, with potentially superior results for some individuals.
  • Considerations: Similar side effect profile to finasteride, but potentially with a slightly higher incidence due to more complete DHT suppression.

2. Topical Treatments

These medications are applied directly to the scalp to stimulate hair growth.

• Minoxidil (Rogaine):
  • Mechanism: Believed to work by increasing blood flow to hair follicles, prolonging the anagen (growth) phase, and stimulating dormant follicles.
  • Dosage: Available as a 2% or 5% solution or foam, typically applied once or twice daily. Oral minoxidil at low doses (e.g., 2.5–5mg daily) is also gaining popularity and may offer systemic benefits.
  • Efficacy: Effective for many, particularly at the crown. It does not block DHT but rather acts as a growth stimulant.
  • Considerations: Requires consistent application; results typically appear after 3–6 months. Side effects can include scalp irritation, unwanted facial hair growth, or temporary shedding initially.
• Topical Finasteride/Dutasteride: These formulations aim to deliver the 5ARI directly to the scalp, potentially reducing systemic absorption and side effects.
  • Mechanism: Localized inhibition of 5AR.
  • Efficacy: Emerging as a promising option, though long-term data for widespread use is still being accumulated.

3. Combination Therapy

The “2026 gold standard” for managing androgenic alopecia involves combining multiple treatment modalities. A 2025 meta-analysis of 396 patients confirmed that combining finasteride and minoxidil outperforms either treatment alone.

This often includes:

• Oral finasteride (e.g., 0.2–1mg daily)
• Topical minoxidil (e.g., 5% solution/foam twice daily or low-dose oral minoxidil)
• Adjunctive therapies such as microneedling.

4. Adjunctive Therapies

• Microneedling: This procedure involves creating microscopic punctures in the scalp, which are thought to stimulate growth factors and improve the absorption of topical treatments like minoxidil.
• Platelet-Rich Plasma (PRP): Involves injecting concentrated platelets from the patient’s own blood into the scalp. Platelets contain growth factors that can stimulate hair follicles.
• Clascoterone: A topical androgen receptor inhibitor, clascoterone works by directly blocking androgen uptake at the follicle, rather than reducing DHT production. Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, with Maria Hordinsky, MD, highlights its potential as a novel treatment option.

Balancing TRT and Hair Preservation

For men on TRT aiming for optimal health, managing potential hair loss requires a proactive approach. It’s not about choosing between health optimization and hair, but rather about integrating strategies. Consistent blood work monitoring for total and free testosterone, estradiol, and PSA (if on 5ARIs) remains paramount.

While some TRT protocols incorporate Human Chorionic Gonadotropin (HCG) at doses like 500–1000 IU per week (split into multiple injections) to maintain testicular function and endogenous testosterone production, HCG itself does not directly impact DHT conversion. Similarly, anastrozole, an aromatase inhibitor, is used to manage high E2 levels (typically when E2 exceeds 40 pg/mL), not hair loss. Enclomiphene, a selective estrogen receptor modulator, stimulates natural testosterone production but its impact on hair loss is similar to exogenous testosterone, as it still provides substrate for 5AR.

A key takeaway from the American Academy of Dermatology’s guidelines is the importance of early intervention. “Hair loss treatments are most effective when started early, before significant follicular miniaturization has occurred,” states their clinical guideline. This underscores the need to address hair loss concerns as soon as they arise, rather than waiting for extensive progression.

Comparison of Hair Loss Prevention Treatments on TRT